The objective of the study is to investigate the effect of hydroxychloroquine (HCQ) on subjective and objective parameters of dry eye in patients with primary Sjogren's disease and to evaluate the association of tear fluid B-cell activating factor (BAFF) level with the response. Thirty-two patients with primary Sjogren's disease were enrolled in this prospective study. All patients included in the study completed at least a 48-month run-in period of using hydroxychloroquine. Patients were then instructed to drop the treatment for 3 months. Baseline and post cessation of treatment (baseline and 3 months) evaluations included, subjective symptom scoring, fluorescein and lissamine green staining, Schirmer's test, tear break-up time (BUT) and tear fluid BAFF assessments. Significant worsening was observed in, tear break up-time (TBUT) (7.9 ± 3.4 vs. 5.9 ± 2.9, P < 0.001) lissamine green of staining of the ocular surface (1.3 ± 0.9 vs. 1.8 ± 0.8, P < 0.01) and corneal fluorescein staining scores (2.2 ± 2.1 vs. 4.6 ± 3.3, P < 0.003) between on and off HCQ treatment, respectively. Similarly, gritty sensation and burning sensation were significantly changed at week 12 compared to baseline evaluation (1.18 ± 1.02 vs. 1.7 ± 1.05, P < 0.007 and 1.1 ± 1.0 vs. 1.6 ± 1.2, P < 0.0, respectively). Disease duration significantly correlated with baseline OSDI (r = 0.38, P < 0.04) and the average daily use of artificial tears (r = 0.36, P < 0.04). The mean BAFF levels were 0.8 ± 0.5 and 4.0 ± 0.7 ng/ml for baseline and week 12 evaluation, respectively (P < 0.0001). The results of this study suggest that HCQ may alleviate symptoms and signs of dry eye in pSS and decreases tear fluid BAFF levels.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00296-010-1415-4 | DOI Listing |
Eye Contact Lens
January 2025
Department of Ophthalmology (B.S., A.S., S.B., J.K.), Emory University School of Medicine, Atlanta, GA; and Emory University School of Medicine (S.C.), Atlanta, GA.
Purpose: Symptom management in Ocular Cicatricial Pemphigoid (OCP) is challenging because of the progressive factors of dry eye, scarring, trichiasis, and vision impairment. We set out to evaluate the benefits and therapeutic effects of scleral contact lenses in the management of OCP.
Methods: A retrospective review was performed over a database of 20 patients (36 eyes) fitted with scleral lenses (SL) at the Department of Ophthalmology, Emory University from May 2018 to April 2021.
J Cell Mol Med
February 2025
Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Mucosa-associated lymphoid tissue (MALT) lymphoma is an extranodal low-grade non-Hodgkin lymphoma that extremely rarely localises to the mediastinum. A 34-year-old female with chronic arthralgia, sicca and rash was found to have a well-demarcated mediastinal cystic mass with equivocal nodular enhancement within the cystic wall on chest CT during a workup for Sjögren's syndrome. Subsequent Ga-Pentixafor-PET/CT revealed focal uptake increase within the cystic capsule.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing, 100730, China.
Meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye disease, presenting a challenge for targeted treatment. Traditional topical ocular drug delivery methods often fail to effectively reach the meibomian glands (MGs). To address this, the study has developed a soluble microneedles (MN) patch comprising poly(vinyl alcohol), cyclodextrin modified polyacrylic acid, and new indocyanine green.
View Article and Find Full Text PDFVopr Kurortol Fizioter Lech Fiz Kult
January 2025
Russian University of Medicine of the Ministry of Health of the Russian Federation, Moscow, Russia.
Objective: To evaluate the effectiveness of a treatment complex including magnetophoresis with the drug «Argensept» and tear therapy in patients with mild to moderate dry eye syndrome.
Material And Methods: The study was conducted on 50 people (100 eyes) diagnosed with mild to moderate dry eye syndrome (H04.1 according to ICD-10).
Front Med (Lausanne)
January 2025
Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!